Outlook Therapeutics, Inc. (NASDAQ:OTLK) CEO Lawrence A. Kenyon acquired 25,000 shares of the stock in a transaction that occurred on Thursday, February 7th. The stock was acquired at an average cost of $0.90 per share, for a total transaction of $22,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
OTLK stock opened at $0.92 on Monday. Outlook Therapeutics, Inc. has a 12-month low of $0.20 and a 12-month high of $0.98.
Separately, ValuEngine cut Outlook Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.